Biophytis is a Euronext and Nasdaq listed late-stage biotech Company based in Paris (www.biophytis.com) with advanced assets currently in phase 2b in Sarcopenia, and in phase 2/3 in severe respiratory manifestations linked to Covid-19. We recently achieved significant clinical progresses:

We recently achieved significant clinical progresses:
– COVA, our phase 2-3 study in COVID-19 has received positive feedback from DMC on the 2nd interim
analysis, being safe and in the promising zone for efficacy
– SARA, our phase 2b study in Sarcopenia has demonstrated clinically meaningful efficacy. Our next inflection point milestones are reporting the full results from COVA study and filling for Emergency Use Approval/Conditional Approval in Q2 2022, targeting a potential commercialization for COVID-19 treatment mid-2022. In Sarcopenia, we are currently preparing our meetings with FDA/EMA in order to design the Phase 3 program by Q4 2021 and initiate clinical activities in 2022. We are currently active in partnership discussions for both indications to trigger new values.

Session 1- COVA project in COVID-19

• KOLs: Dr Girish Balachandran Nair (USA) and Pr Suzana Lobo (Brazil)
• Biophytis representatives: Stanislas Veillet (CEO), Rob Van Maanen (CMO) and Evelyne Nguyen (CFO)

Session 2- SARA project in Sarcopenia

• Oct 6th, 6.45 to 7.30pm, CET
• KOLs: Pr Bruno Vellas (France) and Dr Roger A. Fielding (USA)
• Biophytis representatives: Stanislas Veillet (CEO), Pr Jean Mariani (Scientific Advisory Board President)
and Evelyne Nguyen (CFO)